Carotid revascularization in patients with ongoing oral anticoagulant therapy: the advantages of stent placement

J Vasc Interv Radiol. 2013 Mar;24(3):370-7. doi: 10.1016/j.jvir.2012.11.027.

Abstract

Purpose: To assess the influence of oral anticoagulant therapy conversion to heparin (OAT-CH) on carotid endarterectomy (CEA) outcomes and the influence of unmodified oral anticoagulant therapy (OAT) on carotid artery stenting (CAS) and to compare the outcomes of CEA in OAT-CH with CAS in ongoing OAT.

Materials and methods: The 30-day results from all patients who underwent CEA and CAS in a 6-year period were analyzed for stroke, death, myocardial infarction (MI), and hematoma of the access site requiring surgical evacuation. We evaluated the influence of OAT-CH in CEA and the influence of OAT in CAS and compared CEA and CAS outcomes in patients receiving OAT-CH and OAT.

Results: Among 1,222 carotid revascularizations, there were 711 CEAs (58.1%) and 511 CAS procedures (41.9%). In the CEA group, 31 (4.4%) patients were treated with OAT-CH, and these patients had a significantly higher complication rate compared with patients not receiving OAT, including death (1 [3.2%] vs 4 [0.6%]; P = .04), stroke (4 [12.9%] vs 10 [1.4%]; P = .001), and hematoma (3 [9.6%] vs 11 [1.6%]; P = .02). In CAS, the results were similar in patients receiving OAT (30 [5.8%]) and patients not receiving OAT. Patients receiving OAT who underwent CAS had better outcomes than patients receiving OAT-CH who underwent CEA, including stroke, death, MI, and hematoma combined (0 [0.0%] vs 7 [22.5%]; P =.01).

Conclusions: OAT management significantly influences the results of carotid revascularization. Because CAS with unmodified OAT had a significantly better outcome than CEA with OAT-CH, carotid revascularization strategies should favor CAS rather than CEA in this setting.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Angioplasty / adverse effects
  • Angioplasty / instrumentation*
  • Angioplasty / mortality
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Carotid Artery Diseases / drug therapy
  • Carotid Artery Diseases / mortality
  • Carotid Artery Diseases / surgery
  • Carotid Artery Diseases / therapy*
  • Chi-Square Distribution
  • Drug Administration Schedule
  • Drug Substitution*
  • Endarterectomy, Carotid* / adverse effects
  • Endarterectomy, Carotid* / mortality
  • Female
  • Hematoma / etiology
  • Heparin / administration & dosage*
  • Heparin / adverse effects
  • Humans
  • Logistic Models
  • Male
  • Multivariate Analysis
  • Myocardial Infarction / etiology
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Stents*
  • Stroke / etiology
  • Time Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Heparin